Bruce E. Johnson
Impact in
- Oncology top 0.01%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 188
- Lung Cancer Diagnosis and Treatment 48
- Oncology 180
- Lung Cancer Research Studies 93
- Colorectal Cancer Treatments and Studies 27
- HER2/EGFR in Cancer Research 21
- Cancer Immunotherapy and Biomarkers 19
- Co-authors
- Pasi A. Jänne (93 shared papers)Matthew Meyerson (18 shared papers)Neal I. Lindeman (23 shared papers)Michael J. Eck (5 shared papers)Titus J. Boggon (3 shared papers)David M. Jackman (36 shared papers)Sean Tracy (4 shared papers)Jeffrey A. Engelman (14 shared papers)
- Journals
- Journal of Clinical Oncology (73 papers)Clinical Cancer Research (34 papers)Journal of Thoracic Oncology (27 papers)Lung Cancer (27 papers)Cancer (19 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Bruce E. Johnson
402 papers receiving 50.5k citations
Bruce E. Johnson's Hit Papers
Peers
Comparison fields: 5 of 191
- Oncology 23.4k
- Pulmonary and Respiratory Medicine 25.8k
- Cancer Research 7.9k
- Molecular Biology 18.4k
- Pathology and Forensic Medicine 3.2k
Countries citing papers authored by Bruce E. Johnson
This map shows the geographic impact of Bruce E. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce E. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce E. Johnson more than expected).
Fields of papers citing papers by Bruce E. Johnson
This network shows the impact of papers produced by Bruce E. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce E. Johnson. The network helps show where Bruce E. Johnson may publish in the future.
Co-authors
The 25 scholars most cited alongside Bruce E. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 424 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy Hit paper breakdown → | 2004 | 7806 |
| 2 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Hit paper breakdown → | 2007 | 3694 |
| 3 | EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Hit paper breakdown → | 2005 | 3252 |
| 4 | A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types Hit paper breakdown → | 1994 | 2432 |
| 5 | Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Hit paper breakdown → | 2001 | 2095 |
| 6 | Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission Hit paper breakdown → | 1999 | 1254 |
| 7 | TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 1248 |
| 8 | Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib Hit paper breakdown → | 2005 | 1238 |
| 9 | Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Hit paper breakdown → | 2017 | 975 |
| 10 | First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations Hit paper breakdown → | 2008 | 684 |
| 11 | Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Hit paper breakdown → | 2009 | 651 |
| 12 | Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial Hit paper breakdown → | 2016 | 633 |
| 13 | Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population Hit paper breakdown → | 2009 | 552 |
| 14 | Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Hit paper breakdown → | 2005 | 539 |
| 15 | Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib Hit paper breakdown → | 2006 | 501 |
| 16 | 1987 | 428 | |
| 17 | 2005 | 427 | |
| 18 | 2005 | 411 | |
| 19 | 2006 | 387 | |
| 20 | c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. | 2003 | 381 |
About Bruce E. Johnson
Bruce E. Johnson is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Epidemiology, having authored 424 papers that have together received 52.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (188 papers), Lung Cancer Research Studies (93 papers), Lung Cancer Diagnosis and Treatment (48 papers), Cancer Genomics and Diagnostics (38 papers), Neuroendocrine Tumor Research Advances (32 papers), Colorectal Cancer Treatments and Studies (27 papers), HER2/EGFR in Cancer Research (21 papers) and Cancer Immunotherapy and Biomarkers (19 papers). The work is most often cited by research in Oncology (23.4k citations), Pulmonary and Respiratory Medicine (25.8k citations), Cancer Research (7.9k citations), Molecular Biology (18.4k citations) and Pathology and Forensic Medicine (3.2k citations). Bruce E. Johnson has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Pasi A. Jänne, Matthew Meyerson, Neal I. Lindeman, Michael J. Eck, Titus J. Boggon, David M. Jackman, Sean Tracy, Jeffrey A. Engelman, Jeffrey C. Lee and Katsuhiko Naoki. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Lung Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.